3 recruiting, 2 active not recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 3, Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 3, Active not recruiting 1 |
Follow MCL: new trials by email Literature Review of MCL trials Research Report on MCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 258 | 2025-01-23 | 2026-10-26 |
| Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). CD19/CD22-CAR T cells - Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2025-08-06 |
| A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Glofitamab, Obinutuzumab, Lenalidomide - Mantle Cell Lymphoma, MCL | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2024-01-08 | 2026-03-27 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Epcoritamab - DLBCL, High-grade B-cell Lymphoma (HGBCL) | Phase 1 / Phase 2 | Active not recruiting | Genmab | 666 | 2018-06-26 | 2026-11-04 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Hematologic Neoplasms (1) · Lymphoma, B-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Hematologic Diseases (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Lymphoma, Non-Hodgkin (4) · Chronic Disease (3) · Disease Attributes (3) · Leukemia, B-Cell (3)
LFB-R603 (1) · Lenalidomide (1) · glofitamab (1) · obinutuzumab (1) · ublituximab (1) · zanubrutinib (1)
BeOne Medicines (1) · Essen Biotech (1) · Genmab (1) · Hutchmed (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Memorial Sloan Kettering Cancer Center (1) · TG Therapeutics, Inc. (1)
United States (5) · Australia (3) · China (3) · France (3) · Italy (2) · Poland (2) · Spain (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Denmark (1) · Finland (1) · Germany (1) · Israel (1) · Netherlands (1)
Anita Kumar, MD (1) · Vijay Jayaprakash, MBBS, PHD (1)
PMID 34508654, PMID 35538512, PMID 36548927, PMID 38151388, PMID 38889737, PMID 39322711, PMID 40472301, PMID 42411504, PMID 42431612, PMID 42541678
2017 (1), 2023 (1)